Vishal Harshvardhan Jain

Vishal Harshvardhan Jain

Active Director Director DIN 08082565
DIN 08082565 First appointment Mar 2018 Primary industry Life Sciences
Unlock full profile Investments · shareholding · contact details
Current companies 2 active board seats
Past companies 3 historical roles
Total affiliations 5 Since Mar 2018
Shareholding value •••• Premium profile

About Vishal Harshvardhan Jain

Data last updated:

Vishal Harshvardhan Jain is a Director at Infinion Biopharma Limited (since 2018) and Director at Amphina Therapeutics Private Limited (since 2020). The companies operate in Life Sciences, Pharma and Travel and Hospitality. The 2 current companies with reported revenue have a combined latest revenue of ₹1.17 Cr; the largest is Infinion Biopharma Limited at ₹91.8 Lakh (FY 2025). Earlier, Vishal Harshvardhan Jain was a Director at Innovate Farmkart Private Limited (2020–2025) and Director at Infinion Lifesciences Private Limited (2022–2025) and 1 more.

DIN 08082565
Primary Designation Director
Industry Life Sciences
First Appointment 10 Mar 2018
Oldest Company Age 8 yrs
Largest company Infinion Biopharma Limited · ₹91.8 Lakh (FY 2025)
Combined revenue ₹1.17 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Infinion Biopharma Limited U51909GJ2018PLC100571
Director10 Mar 20182018₹91.8 Lakh (FY 2025)Active
Amphina Therapeutics Private Limited U85100GJ2020PTC112901
Director03 Mar 20202020₹25.4 Lakh (FY 2025)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Innovate Farmkart Private Limited U85300GJ2020PTC112885
Director03 Mar 20202020Active
Director21 Jul 20222022Active
Director26 May 20222022Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Vishal Harshvardhan Jain

Directorship timeline

Open interactive timeline →
Infinion Biopharma Limited
Amphina Therapeutics Private Limited
Innovate Farmkart Private Limited
Infinion Lifesciences Private Limited
Premium access

Shareholding and investment profile for Vishal Harshvardhan Jain

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vishal Harshvardhan Jain

Vishal Harshvardhan Jain currently holds 2 directorships: Infinion Biopharma Limited (Director, since 10 Mar 2018, revenue ₹91.8 Lakh (FY 2025)); Amphina Therapeutics Private Limited (Director, since 03 Mar 2020, revenue ₹25.4 Lakh (FY 2025)).

Vishal Harshvardhan Jain was first appointed on 10 Mar 2018 as Director at Infinion Biopharma Limited. The most recent appointment on record is 21 Jul 2022 at Infinion Lifesciences Private Limited.

The 2 current companies of Vishal Harshvardhan Jain that report revenue have a combined latest revenue of ₹1.17 Cr: Infinion Biopharma Limited ₹91.8 Lakh (FY 2025); Amphina Therapeutics Private Limited ₹25.4 Lakh (FY 2025).

Vishal Harshvardhan Jain held 3 earlier board appointments: Innovate Farmkart Private Limited (Director, 03 Mar 2020 to 26 Feb 2025); Infinion Lifesciences Private Limited (Director, 21 Jul 2022 to 26 Feb 2025); Celliimune Therapeutics Private Limited (Director, 26 May 2022 to 18 Oct 2022).

The current boards of Vishal Harshvardhan Jain's companies include Dhruv Desai (Infinion Biopharma Limited), Gautam Bali (Infinion Biopharma Limited), Pankaj Kumar Singh (Infinion Biopharma Limited), Shivani Pathak (Infinion Biopharma Limited), Govindsingh Bhavansinh Chavda (Amphina Therapeutics Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available